Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and tolerability study of lumateperone adjunctive therapy in major depressive disorder
2021-001172-41Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumateperone in major depressive disorder (MDD), sponsored by Intra-Cellular Therapies. Primary endpoints: Change from baseline in Montgomery-Asberg Depression Rating Scale total score, Change from baseline in Clinical Global Impression-Severity score and 1 more. Started Oct 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-001172-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001172-41.